Mechanism of synergy between epigallocatechin gallate and β-lactams against methicillin-resistant Staphylococcus aureus

被引:290
作者
Zhao, WH
Hu, ZQ
Okubo, S
Hara, Y
Shimamura, T
机构
[1] Showa Univ, Sch Med, Dept Microbiol & Immunol, Shinagawa Ku, Tokyo 1428555, Japan
[2] Tokyo Food Techno Co Ltd, Tokyo, Japan
关键词
D O I
10.1128/AAC.45.6.1737-1742.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Compared to MICs (more than 800 mug/ml) of (-)-epigallocatechin gallate (EGCg) against Escherchia coli, MICs of EGCg against methicillin-susceptible and methicillin-resistant Staphylococcus aureus (MSSA and MRSA) were 100 mug/ml or less. Furthermore, less than 25 pg EGCg per mi obviously reversed the high level resistance of MRSA to all types of tested beta -lactams, including benzylpenicillin, oxacillin, methicillin, ampicillin, and cephalexin, EGCg also induced a supersusceptibility to beta -lactams in MSSA which does not express mecA, encoding penicillin-binding protein 2' (PBP2'), The fractional inhibitory concentration (FIC) indices of the tested beta -lactams against 25 isolates of MRSA were from 0.126 to 0.625 in combination,vith 6.25, 12.5 or 25 mug of EGCg per ml. However, no synergism was observed between EGCg and ampicillin against E, coli, EGCg largely reduced the tolerance of MRSA and MSSA to high ionic strength and low osmotic pressure in their external atmosphere, indicating damage of the cell wall. Unlike dextran and lipopolysaccharide, peptidoglycan from S, aureus blocked both the antibacterial activity of EGCg and the synergism between EGCg and oxacillin, suggesting a direct binding of EGCg with peptidoglycan on the cell wall. EGCg showed a synergistic effect with DL-cycloserine tan inhibitor of cell wall synthesis unrelated to PBP2') but additive or indifferent effect with inhibitors of protein and nuclear acid synthesis. EGCg did not suppress either PBP2' mRNA expression or PBP2' production, as confirmed by reverse transcription-PCR and a semiquantitative PBP2' latex agglutination assay, indicating an irrelevance between the synergy and PBP2' production. In summary, both EGCg and beta -lactams directly or indirectly attack the same site, peptidoglycan on the cell wall. EGCg synergizes the activity of beta -lactams against MRSA owing to interference with the integrity of the cell wall through direct binding to peptidoglycan.
引用
收藏
页码:1737 / 1742
页数:6
相关论文
共 26 条
[1]   Penicillin-binding protein-mediated resistance in pneumococci and staphylococci [J].
Chambers, HF .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 :S353-S359
[2]  
Chen LS, 1997, DRUG METAB DISPOS, V25, P1045
[3]   MOLECULAR ASPECTS OF METHICILLIN RESISTANCE IN STAPHYLOCOCCUS-AUREUS [J].
DELENCASTRE, H ;
DEJONGE, BLM ;
MATTHEWS, PR ;
TOMASZ, A .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1994, 33 (01) :7-24
[4]   SERINE BETA-LACTAMASES AND PENICILLIN-BINDING PROTEINS [J].
GHUYSEN, JM .
ANNUAL REVIEW OF MICROBIOLOGY, 1991, 45 :37-67
[5]  
Hamilton-Miller J.M.T., 1997, CHEM BIOL PROPERTIES, P63
[6]   ANTIMICROBIAL PROPERTIES OF TEA (CAMELLIA-SINENSIS L) [J].
HAMILTONMILLER, JMT .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (11) :2375-2377
[7]   LOW-AFFINITY PENICILLIN-BINDING PROTEIN ASSOCIATED WITH BETA-LACTAM RESISTANCE IN STAPHYLOCOCCUS-AUREUS [J].
HARTMAN, BJ ;
TOMASZ, A .
JOURNAL OF BACTERIOLOGY, 1984, 158 (02) :513-516
[8]   Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk [J].
Herold, BC ;
Immergluck, LC ;
Maranan, MC ;
Lauderdale, DS ;
Gaskin, RE ;
Boyle-Vavra, S ;
Leitch, CD ;
Daum, RS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (08) :593-598
[9]   BACTERICIDAL CATECHINS DAMAGE THE LIPID BILAYER [J].
IKIGAI, H ;
NAKAE, T ;
HARA, Y ;
SHIMAMURA, T .
BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1147 (01) :132-136
[10]   Comparison of susceptibility testing methods with mecA gene analysis for determining oxacillin (methicillin) resistance in clinical isolates of Staphylococcus aureus and coagulase-negative Staphylococcus spp. [J].
Kohner, P ;
Uhl, J ;
Kolbert, C ;
Persing, D ;
Cockerill, F .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (09) :2952-2961